New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
07:06 EDTAGEN, BMYAgenus initiates Prophage Phase 2 trial
Agenus (AGEN) announced initiation of a randomized Phase 2 trial with Prophage for melanoma, and Bristol-Myers Squibb's (BMY) Yervoy for the treatment of Stage III and IV metastatic melanoma. The combination has the potential to trigger a more effective immune response against the tumor than Yervoy alone. The Phase 2, randomized, open label, single-center, investigator-sponsored trial is designed to evaluate the safety, feasibility and immunogenicity of the combination of Prophage vaccine and Yervoy with or without low dose cyclophosphamide in 25 patients with unresectable Stage III or IV metastatic melanoma. Jorge Quesada, principal investigator of the study said "The combination may improve the prospects for patients who do not respond to ipilimumab alone, which is approximately 70% of the metastatic melanoma patients."
News For AGEN;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
08:14 EDTBMYPortola announces Phase 3 ANNEXA study met primary, secondary endpoints
Subscribe for More Information
07:52 EDTBMYJ&J purchase of Alios an incremental negative for Achillion, says UBS
UBS views Johnson & Johnson's (JNJ) purchase of Alios as an incremental negative for Achillion (ACHN), as it implies there is now one less potential buyer of the company. However, the firm still thinks ACH-3422 will have considerable strategic value after data is reported and that other HCV players such as AbbVie (ABBV) and Bristol-Myers (BMY) are likely to be interested. UBS maintains its Buy rating and $15 price target on Achillion.
September 30, 2014
17:02 EDTBMYBristol-Myers to transfer $1.4B in U.S. pension obligations to Prudential
Subscribe for More Information
16:39 EDTBMYCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
September 29, 2014
08:22 EDTBMYBristol-Myers says EMA validates MAA for Nivolumab in NSCLC
Bristol-Myers Squibb announced that the European Medicines Agency has validated for review the Marketing Authorization Application for nivolumab in non-small cell lung cancer– the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type. The MAA submitted to the EMA in lung cancer is based on data from the Phase 2 study of nivolumab in third-line pre-treated squamous cell NSCLC. In addition to the MAA for lung cancer in the E.U., the company previously announced that it has initiated a rolling submission with the FDA for Opdivo in third-line pre-treated squamous cell NSCLC and expects to complete the submission by year-end.
07:26 EDTBMYInforma Business Information to hold a conference
Subscribe for More Information
05:32 EDTBMYBristol-Myers announces positive Phase 3 data for Opdivo
Subscribe for More Information
September 26, 2014
16:20 EDTBMYBristol-Myers announces multiple regulatory milestones for Opdivo in U.S., EU
Subscribe for More Information
September 23, 2014
12:10 EDTBMYBristol-Myers to build 650,000 square foot campus in Lawrenceville, NJ
Subscribe for More Information
September 22, 2014
07:21 EDTBMYEBD Group to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use